Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2009 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | ANN-LII CHENG ; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. | The Lancet Oncology | 4127 | 3977 | |
2012 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial | ANN-LII CHENG ; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. | European Journal of Cancer | 188 | ||
2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU ; Chang W.-C.; Kuo H.-P.; Yu C.-T.; Lin Z.-Z.; Kao W.-Y. | Lung Cancer | 28 | 26 | |
2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y. | Lung Cancer | 26 | ||
1996 | Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside - The Taiwan experience | Chen Y.-C.; Lin S.-F.; MING YAO ; Chen T.-Y.; Tsao C.-J.; Chen T.-P. | Seminars in Hematology | 8 | ||
1996 | Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside - The Taiwan experience | YAO-CHANG CHEN ; Lin S.-F.; Yao M.; Chen T.-Y.; Tsao C.-J.; Chen T.-P. | Seminars in Hematology | 8 | ||
2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. | World Journal of Gastroenterology | 14 | ||
2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. | World Journal of Gastroenterology | 17 | 14 | |
2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. | World Journal of Gastroenterology | 14 | ||
2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN | World Journal of Gastroenterology | 14 | ||
2011 | PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma | Abou-Alfa G.K; Chan S.L; Chia-Chi Lin ; Chiorean E.G; Holcombe R.F; Mulcahy M.F; Carter W.D; Patel K; Wilson W.R; Melink T.J; Gutheil J.C; Tsao C.-J. | Cancer Chemotherapy and Pharmacology | 25 | 24 | |
1993 | Serum lymphocyte subpopulations and immunoglobulins in gastric cancer patients: A comparative study between earlier and more advanced stages | Lee J.-C.; Lin P.-W.; Huang S.-M.; Tsao C.-J.; HONG-SHIEE LAI ; Chang K.-J. | Journal of Surgical Association Republic of China | 0 | ||
2003 | Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma | Cheng A.-L.; Hsiung C.A.; Su I.-J.; Chen P.-J.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J. | Hepatology | 246 | 219 | |
2003 | Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma | ANN-LII CHENG ; Hsiung C.A.; Su I.-J.; Chen P.-J.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J. | Hepatology | 246 | 219 | |
2003 | Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma | Cheng A.-L.; Hsiung C.A.; Su I.-J.; Chen P.-J.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J. | Hepatology | 219 | ||
2003 | Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma | Cheng A.-L.; Hsiung C.A.; Su I.-J.; PEI-JER CHEN ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J. | Hepatology | 219 | ||
1997 | Weekly CAF chemotherapy for advanced breast cancer patients | Hwang W.-S.; Hsiung C.A.; Ko W.-S.; lVang C.-C.; Chang J.-V.; Lai G.-M.; Hsieh R.-K.; Tsao C.-J.; Chen L.-T.; Law C.-K.; ANN-LII CHENG ; Fan S.F.; Tzeng C.-H.; Chiou T.-J.; Whang-Peng J. | Oncology (Switzerland) | 1 | 1 |